Skip to main content

Value Stock - Dividend - Research Selection


Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent

- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after a single dose of afami-cel -- Overall response rate in synovial sarcoma of 39% by independent review -consistent with previous data - -Median duration of response of 50 weeks, consistent with previous data -- Afami-cel drives tumor infiltration of activated and proliferative cytotoxic ("killer") T-cells into tumors - which likely contributes to ant

Poseida Therapeutics: Early Stage CAR-T Developer Seeing Big Pharma Interest

Poseida Therapeutics is a very early stage CAR-T and gene therapy developer. Click here for a full investment analysis of PSTX stock.

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Celebrations may be in order for Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders, with the analysts...

Lab notes: Adaptimmune to reduce workforce; NRx completes $11M debt financing

This week's Lab Notes has items on a cell therapy developer joining the list of life sciences companies making staff reductions, a multimillion-dollar debt financing deal, an update on a company's efforts to develop biosimilar products and more. Here's the Roundup AdaptImmune (NASDAQ: ADAP) The cell therapy developer with operations in Philadelphia and Oxford, England, said this week it is cutting its workforce by 25% to 30% and narrowing its research focus to conserve cash. The company also said it is prioritizing its two lead T-cell therapy programs targeting solid tumors.

5 Penny Stocks To Buy According To Analysts, Targets Up To 353%

Analysts say these are penny stocks to buy. Do you agree?

Adaptimmune Therapeutics Third Quarter 2022 Earnings: Beats Expectations

Adaptimmune Therapeutics ( NASDAQ:ADAP ) Third Quarter 2022 Results Key Financial Results Revenue: US$7.01m (up 483...

Adaptimmune management to meet with Roth Capital

Meeting to be held in San... ADAP

SVB Securities Sticks to Their Hold Rating for Adaptimmune Therapeutics (ADAP)

SVB Securities analyst Jonathan Chang reiterated a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) on November 8 and set a price target of $3...

Adaptimmune upgraded to Buy from Neutral at Mizuho

Mizuho analyst Mara Golds... ADAP

Why Adaptimmune Therapeutics Stock Is Glowing Green Today

Shares of the anti-cancer cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having an unusually strong showing today. Ahead of the opening bell, Adaptimmune released both its third-quarter earnings and a clinical program update for its MAGE-A4 franchise. In an exploratory study of patients with various solid tumors, the company's modified T-cell therapy, known as ADP-A2M4CD8, reportedly produced an overall response rate of 43% in patients with advanced ovarian cancer.